Cargando…

Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017

BACKGROUND: After the scale-up of antiretroviral therapy (ART) for HIV infected people, increasing numbers of patients have pretreatment drug resistance (PDR). In this study, the prevalence of PDR was evaluated in adults initiating antiretroviral therapy in China. METHODS: Blood samples were obtaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Rui-Hua, Liang, Shu-Jia, Ma, Yan-Ling, Liang, Shu, Xiao, Lin, Zhang, Xin-Hui, Lu, Hong-Yan, Xu, Xiao-Qin, Luo, Shui-Bin, Sun, Xiao-Guang, Chen, Lin, He, Jian-Mei, Wu, Guo-Hui, Liao, Ling-Jie, Xing, Hui, Shao, Yi-Ming, Ruan, Yu-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247188/
https://www.ncbi.nlm.nih.gov/pubmed/32448388
http://dx.doi.org/10.1186/s40249-020-00668-5
_version_ 1783538107531919360
author Kang, Rui-Hua
Liang, Shu-Jia
Ma, Yan-Ling
Liang, Shu
Xiao, Lin
Zhang, Xin-Hui
Lu, Hong-Yan
Xu, Xiao-Qin
Luo, Shui-Bin
Sun, Xiao-Guang
Chen, Lin
He, Jian-Mei
Wu, Guo-Hui
Liao, Ling-Jie
Xing, Hui
Shao, Yi-Ming
Ruan, Yu-Hua
author_facet Kang, Rui-Hua
Liang, Shu-Jia
Ma, Yan-Ling
Liang, Shu
Xiao, Lin
Zhang, Xin-Hui
Lu, Hong-Yan
Xu, Xiao-Qin
Luo, Shui-Bin
Sun, Xiao-Guang
Chen, Lin
He, Jian-Mei
Wu, Guo-Hui
Liao, Ling-Jie
Xing, Hui
Shao, Yi-Ming
Ruan, Yu-Hua
author_sort Kang, Rui-Hua
collection PubMed
description BACKGROUND: After the scale-up of antiretroviral therapy (ART) for HIV infected people, increasing numbers of patients have pretreatment drug resistance (PDR). In this study, the prevalence of PDR was evaluated in adults initiating antiretroviral therapy in China. METHODS: Blood samples were obtained from 1943 patients who initiated antiretroviral therapy (ART) in 2017 from 13 provinces or cities in China. Pol sequences were used to analyze drug resistance and construct transmission networks. Logistic regression model was used to estimate the potential factors associated with PDR. RESULTS: In total, 1711 eligible patients (76.0% male; 87.8% aged ≥ 25 years) were included, of which 117 (6.8%) had PDR. The highest rates of PDR were 12.2% in Liangshan Prefecture of Sichuan and 9.3 and 8.9% in Dehong and Lincang Prefecture of Yunnan. A multivariate logistic regression analysis revealed that PDR was significantly higher among intravenous drug users (adjusted Odds Ratio (aOR) = 2.64, 95% CI: 1.57–4.44) and individuals from Liangshan, Dehong, and Lincang (aOR = 2.04, 95% CI: 1.26–3.30). In total, 754 sequences were used to generate 164 transmission networks. Five transmission networks had two or three sequences containing the same mutations, two networks contained subjects from Liangshan, and one network contained subjects from Dehong. CONCLUSIONS: Overall, the PDR prevalence was moderate, with a particularly high prevalence in areas with severe HIV epidemics. These results indicate the importance of continuous PDR monitoring in patients initiating antiretroviral therapy.
format Online
Article
Text
id pubmed-7247188
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72471882020-06-01 Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017 Kang, Rui-Hua Liang, Shu-Jia Ma, Yan-Ling Liang, Shu Xiao, Lin Zhang, Xin-Hui Lu, Hong-Yan Xu, Xiao-Qin Luo, Shui-Bin Sun, Xiao-Guang Chen, Lin He, Jian-Mei Wu, Guo-Hui Liao, Ling-Jie Xing, Hui Shao, Yi-Ming Ruan, Yu-Hua Infect Dis Poverty Research Article BACKGROUND: After the scale-up of antiretroviral therapy (ART) for HIV infected people, increasing numbers of patients have pretreatment drug resistance (PDR). In this study, the prevalence of PDR was evaluated in adults initiating antiretroviral therapy in China. METHODS: Blood samples were obtained from 1943 patients who initiated antiretroviral therapy (ART) in 2017 from 13 provinces or cities in China. Pol sequences were used to analyze drug resistance and construct transmission networks. Logistic regression model was used to estimate the potential factors associated with PDR. RESULTS: In total, 1711 eligible patients (76.0% male; 87.8% aged ≥ 25 years) were included, of which 117 (6.8%) had PDR. The highest rates of PDR were 12.2% in Liangshan Prefecture of Sichuan and 9.3 and 8.9% in Dehong and Lincang Prefecture of Yunnan. A multivariate logistic regression analysis revealed that PDR was significantly higher among intravenous drug users (adjusted Odds Ratio (aOR) = 2.64, 95% CI: 1.57–4.44) and individuals from Liangshan, Dehong, and Lincang (aOR = 2.04, 95% CI: 1.26–3.30). In total, 754 sequences were used to generate 164 transmission networks. Five transmission networks had two or three sequences containing the same mutations, two networks contained subjects from Liangshan, and one network contained subjects from Dehong. CONCLUSIONS: Overall, the PDR prevalence was moderate, with a particularly high prevalence in areas with severe HIV epidemics. These results indicate the importance of continuous PDR monitoring in patients initiating antiretroviral therapy. BioMed Central 2020-05-24 /pmc/articles/PMC7247188/ /pubmed/32448388 http://dx.doi.org/10.1186/s40249-020-00668-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kang, Rui-Hua
Liang, Shu-Jia
Ma, Yan-Ling
Liang, Shu
Xiao, Lin
Zhang, Xin-Hui
Lu, Hong-Yan
Xu, Xiao-Qin
Luo, Shui-Bin
Sun, Xiao-Guang
Chen, Lin
He, Jian-Mei
Wu, Guo-Hui
Liao, Ling-Jie
Xing, Hui
Shao, Yi-Ming
Ruan, Yu-Hua
Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title_full Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title_fullStr Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title_full_unstemmed Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title_short Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
title_sort pretreatment hiv drug resistance in adults initiating antiretroviral therapy in china, 2017
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247188/
https://www.ncbi.nlm.nih.gov/pubmed/32448388
http://dx.doi.org/10.1186/s40249-020-00668-5
work_keys_str_mv AT kangruihua pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT liangshujia pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT mayanling pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT liangshu pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT xiaolin pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT zhangxinhui pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT luhongyan pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT xuxiaoqin pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT luoshuibin pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT sunxiaoguang pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT chenlin pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT hejianmei pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT wuguohui pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT liaolingjie pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT xinghui pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT shaoyiming pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017
AT ruanyuhua pretreatmenthivdrugresistanceinadultsinitiatingantiretroviraltherapyinchina2017